Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been assigned a consensus recommendation of “Hold” from the twenty ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $70.33.

RARE has been the topic of several recent analyst reports. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Canaccord Genuity set a $98.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, July 28th. BidaskClub cut Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reissued a “hold” rating and issued a $68.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. Finally, J P Morgan Chase & Co set a $76.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, August 23rd.

Shares of Ultragenyx Pharmaceutical (RARE) opened at 52.43 on Thursday. The company has a 50 day moving average price of $53.61 and a 200 day moving average price of $59.29. Ultragenyx Pharmaceutical has a 1-year low of $49.56 and a 1-year high of $91.35. The company’s market capitalization is $2.23 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period in the prior year, the firm earned ($1.46) earnings per share. Equities analysts predict that Ultragenyx Pharmaceutical will post ($7.14) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Ultragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of “Hold” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/19/ultragenyx-pharmaceutical-inc-rare-receives-consensus-rating-of-hold-from-brokerages.html.

In other news, CEO Emil D. Kakkis acquired 7,500 shares of the business’s stock in a transaction on Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, with a total value of $393,900.00. Following the transaction, the chief executive officer now owns 430,569 shares in the company, valued at approximately $22,613,483.88. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 9.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in RARE. BlackRock Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 102,249.1% during the first quarter. BlackRock Inc. now owns 3,166,680 shares of the biopharmaceutical company’s stock valued at $214,637,000 after purchasing an additional 3,163,586 shares during the last quarter. State Street Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 21.4% during the second quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock valued at $95,417,000 after purchasing an additional 270,729 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Ultragenyx Pharmaceutical by 933.2% during the second quarter. Royal Bank of Canada now owns 224,261 shares of the biopharmaceutical company’s stock valued at $13,929,000 after purchasing an additional 202,556 shares during the last quarter. Capital International Investors lifted its holdings in shares of Ultragenyx Pharmaceutical by 9.1% during the second quarter. Capital International Investors now owns 2,374,985 shares of the biopharmaceutical company’s stock valued at $147,510,000 after purchasing an additional 198,252 shares during the last quarter. Finally, Pictet Asset Management Ltd. lifted its holdings in shares of Ultragenyx Pharmaceutical by 41.7% during the second quarter. Pictet Asset Management Ltd. now owns 589,211 shares of the biopharmaceutical company’s stock valued at $31,729,000 after purchasing an additional 173,433 shares during the last quarter. Hedge funds and other institutional investors own 96.07% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.